(Reuters) - When asked whether Novartis was interested in buying U.S. biotechnology firm MedImmune , Vasella said biotech firms were "on our radar screen," but declined to comment further.
"It is possible that we do both, acquisitions and share buybacks ," Vasella said in an interview in newspaper Finanz und Wirtschaft.
Read more at Reuters.com Mergers News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment